Peter Stenvinkel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6599639/peter-stenvinkel-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

579 papers	32,583 citations	91 h-index	158 g-index
640 ext. papers	37,388 ext. citations	5.5 avg, IF	7.3 L-index

#	Paper	IF	Citations
579	Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy.. *Scientific Reports*, **2022**, 12, 470	4.9	3
578	Emerging Role of Clinical Genetics in CKD.. *Kidney Medicine*, **2022**, 4, 100435	2.8	1
577	Inflammation in chronic kidney disease **2022**, 91-105		0
576	Nutritional management of chronic peritoneal dialysis patients **2022**, 593-606		
575	Premature vascular aging and senescence in chronic kidney disease **2022**, 263-279		1
574	Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification.. *Clinical and Translational Medicine*, **2022**, 12, e682	5.7	1
573	Does gestational diabetes increase the risk of maternal kidney disease? A Swedish national cohort study.. *PLoS ONE*, **2022**, 17, e0264992	3.7	0
572	Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.. *Scientific Reports*, **2022**, 12, 4414	4.9	3
571	Angiotensin-converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end-stage kidney disease.. *European Journal of Clinical Investigation*, **2022**, e13786	4.6	0
570	Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases.. *Biochimica Et Biophysica Acta - General Subjects*, **2022**, 130129	4	2
569	Cellular mechanisms of aging and their impact on the aortic/arterial wall **2022**, 391-405		
568	Brazil nut supplementation does not affect trimethylamine-n-oxide plasma levels in patients with coronary artery disease.. *Journal of Food Biochemistry*, **2022**, e14201	3.3	1
567	Resistant Starch Type-2 Supplementation Does Not Decrease Trimethylamine N-Oxide (TMAO) Plasma Level in Hemodialysis Patients. **2022**, 1-8		
566	Fermented food: Should patients with cardiometabolic diseases go back to an early neolithic diet?. *Critical Reviews in Food Science and Nutrition*, **2022**, 1-24	11.5	0
565	Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 665-672	4.5	2
564	High-sensitivity troponins in dialysis patients: variation and prognostic value. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1789-1797	4.5	1
563	Muscle Mass Assessed by Computed Tomography at the Third Lumbar Vertebra Predicts Patient Survival in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2021**, 31, 342-350	3	3

562	Sarcopenia in chronic kidney disease: what have we learned so far?. *Journal of Nephrology*, **2021**, 34, 1347-1372	4.8	61
561	Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. *Nutrition Reviews*, **2021**, 79, 1204-1224	6.4	14
560	The oxygen cascade in patients treated with hemodialysis and native high-altitude dwellers: lessons from extreme physiology to benefit patients with end-stage renal disease. *American Journal of Physiology - Renal Physiology*, **2021**, 320, F249-F261	4.3	3
559	Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2021**, 4, e211263	10.4	11
558	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10
557	Methods and rationale of the DISCOVER CKD global observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1570-1578	4.5	1
556	Patient-Reported Measures and Lifestyle Are Associated With Deterioration in Nutritional Status in CKD Stage 4-5: The EQUAL Cohort Study. *Journal of Renal Nutrition*, **2021**,	3	2
555	A biomimetic natural sciences approach to understanding the mechanisms of ageing in burden of lifestyle diseases. *Clinical Science*, **2021**, 135, 1251-1272	6.5	1
554	Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition. *Journal of Internal Medicine*, **2021**, 290, 910-921	10.8	2
553	Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. *Antioxidants and Redox Signaling*, **2021**, 35, 1426-1448	8.4	12
552	MO069SARS-COV-2 RECEPTOR ACE-2, TMPRSS2 AND SOLUBLE ACE-2 IN PATIENTS WITH END STAGE KIDNEY DISEASE. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	78
551	Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. *Bone*, **2021**, 147, 115909	4.7	
550	Socioeconomic position links circulatory microbiota differences with biological age. *Scientific Reports*, **2021**, 11, 12629	4.9	3
549	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. *Kidney International*, **2021**, 100, 1101-1111	9.9	4
548	Potential natural immunization against atherosclerosis in hibernating bears. *Scientific Reports*, **2021** , 11, 12120	4.9	3
547	From the distinctive smell to therapeutic effects: Garlic for cardiovascular, hepatic, gut, diabetes and chronic kidney disease. *Clinical Nutrition*, **2021**, 40, 4807-4819	5.9	5
546	Classification of Uremic Toxins and Their Role in Kidney Failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**,	6.9	15
545	High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients. *Peritoneal Dialysis International*, **2021**, 41, 236-243	2.8	6

544	SARS-COV-2 and biomimetics: What saves the planet will save our health. *Journal of Internal Medicine*, **2021**, 289, 244-246	10.8	3
543	The sweet side of dark chocolate for chronic kidney disease patients. *Clinical Nutrition*, **2021**, 40, 15-26	5.9	4
542	To bee or not to bee? The bee extract propolis as a bioactive compound in the burden of lifestyle diseases. *Nutrition*, **2021**, 83, 111094	4.8	10
541	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. *Nature Reviews Nephrology*, **2021**, 17, 153-171	14.9	41
540	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. *Journal of Bone and Mineral Metabolism*, **2021**, 39, 260-269	2.9	2
539	Biomimetics provides lessons from nature for contemporary ways to improve human health. *Journal of Clinical and Translational Science*, **2021**, 5, e128	0.4	0
538	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. *American Journal of Nephrology*, **2021**, 52, 180-189	4.6	11
537	Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. *Calcified Tissue International*, **2021**, 108, 452-460	3.9	5
536	Role of Uremic Toxins in Early Vascular Ageing and Calcification. *Toxins*, **2021**, 13,	4.9	5
535	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. *PLoS ONE*, **2021**, 16, e0247623	3.7	3
534	Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions, and relation to morbidity. *Nephrology Dialysis Transplantation*, **2021**,	4.3	8
533	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. *Journal of Advanced Research*, **2021**, 31, 49-60	13	11
532	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. *Kidney International Reports*, **2021**, 6, 1775-1787	4.1	26
531	Manipulating the exposome to enable better ageing. *Biochemical Journal*, **2021**, 478, 2889-2898	3.8	4
530	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden - a decade of follow-up. *Transplant International*, **2021**, 34, 2363-2370	3	1
529	Reply letter- critical comments on the impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2021**, 40, 5521-5522	5.9	
528	Renal function and lipid metabolism are major predictors of circumpapillary retinal nerve fiber layer thickness-the LIFE-Adult Study. *BMC Medicine*, **2021**, 19, 202	11.4	2
527	Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. *Biology of Sex Differences*, **2021**, 12, 50	9.3	2

526	Cardiovascular Disease and Inflammation **2021**, 1-22		
525	Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears. *Scientific Reports*, **2020**, 10, 20323	4.9	13
524	Can nutritional interventions modulate the activation of the NLRP3 inflammasome in chronic kidney disease?. *Food Research International*, **2020**, 136, 109306	7	7
523	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?. *Toxins*, **2020**, 12,	4.9	9
522	Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. *BMC Nephrology*, **2020**, 21, 218	2.7	4
521	Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality. *Clinical and Experimental Immunology*, **2020**, 201, 94-104	6.2	4
520	Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. *Nephrology Dialysis Transplantation*, **2020**, 35, ii31-ii37	4.3	33
519	Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
518	Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. *BMC Nephrology*, **2020**, 21, 43	2.7	3
517	Nrf2 in early vascular ageing: Calcification, senescence and therapy. *Clinica Chimica Acta*, **2020**, 505, 108-118	6.18	31
516	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
515	The One Health concept - the health of humans is intimately linked with the health of animals and a sustainable environment. *Journal of Internal Medicine*, **2020**, 287, 223-225	10.8	3
514	Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. *Bone* , **2020**, 133, 115242	4.7	10
513	Risk of long-term renal disease in women with a history of preterm delivery: a population-based cohort study. *BMC Medicine*, **2020**, 18, 66	11.4	4
512	Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2020**, 39, 3594-3600	5.9	32
511	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. *Scientific Reports*, **2020**, 10, 6586	4.9	28
510	Pro-neurotensin depends on renal function and is related to all-cause mortality in chronic kidney disease. *European Journal of Endocrinology*, **2020**, 183, 233-244	6.5	7
509	Protein-Energy Wasting/Malnutrition and the Inflammatory Response **2020**, 413-429		

508	Biomimetics - Nature's roadmap to insights and solutions for burden of lifestyle diseases. *Journal of Internal Medicine*, **2020**, 287, 238-251	10.8	21
507	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. *Bone*, **2020**, 130, 115075	4.7	10
506	Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. *Journal of Internal Medicine*, **2020**, 287, 252-262	10.8	34
505	Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. *Journal of Nephrology*, **2020**, 33, 803-816	4.8	3
504	Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder. *Clinica Chimica Acta*, **2020**, 501, 198-206	6.2	29
503	Phenotypic features of vascular calcification in chronic kidney disease. *Journal of Internal Medicine*, **2020**, 287, 422-434	10.8	6
502	Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees. *Toxins*, **2020**, 12,	4.9	9
501	Intestinal alkaline phosphatase modulation by food components: predictive, preventive, and personalized strategies for novel treatment options in chronic kidney disease. *EPMA Journal*, **2020**, 11, 565-579	8.8	5
500	Design and methodology of the Aging Nephropathy Study (AGNES): a prospective cohort study of elderly patients with chronic kidney disease. *BMC Nephrology*, **2020**, 21, 461	2.7	2
499	Bone mineral density and mortality in end-stage renal disease patients. *CKJ: Clinical Kidney Journal*, **2020**, 13, 307-321	4.5	13
498	Incidence of Fractures Before and After Dialysis Initiation. *Journal of Bone and Mineral Research*, **2020**, 35, 2372-2380	6.3	3
497	Fractures after kidney transplantation: Incidence, predictors, and association with mortality. *Bone*, **2020**, 140, 115554	4.7	7
496	Klotho, Aging, and the Failing Kidney. *Frontiers in Endocrinology*, **2020**, 11, 560	5.7	39
495	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. *Nephrology Dialysis Transplantation*, **2020**, 35, 2059-2072	4.3	9
494	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. *PLoS Medicine*, **2020**, 17, e1003255	11.6	13
493	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, 1202-1211	4.3	11
492	Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. *Nephrology Dialysis Transplantation*, **2020**, 35, 478-487	4.3	10
491	Dietary Patterns and Mortality in a Multinational Cohort of Adults Receiving Hemodialysis. *American Journal of Kidney Diseases*, **2020**, 75, 361-372	7.4	6

490	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2-lessons from evolution, the animal kingdom and rare progeroid syndromes. *Nephrology Dialysis Transplantation*, **2020**, 35, 2036-2045	4.3	35
489	Inflammation and Premature Ageing in Chronic Kidney Disease. *Toxins*, **2020**, 12,	4.9	50
488	Adverse Pregnancy Outcomes and Long-term Maternal Kidney Disease: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2020**, 3, e1920964	10.4	31
487	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
486	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
485	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
484	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
483	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
482	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255		
481	Associations of Chronic Inflammation, Insulin Resistance, and Severe Obesity With Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease. *JAMA Network Open*, **2019**, 2, e1910456	10.4	25
480	Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. *European Journal of Internal Medicine*, **2019**, 68, 60-65	3.9	13
479	Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 250-260	6.9	47
478	A distinct bone phenotype in ADPKD patients with end-stage renal disease. *Kidney International*, **2019**, 95, 412-419	9.9	15
477	Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease. *Computational and Structural Biotechnology Journal*, **2019**, 17, 721-729	6.8	44
476	Cranberries - potential benefits in patients with chronic kidney disease. *Food and Function*, **2019**, 10, 3103-3112	6.1	15
475	Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. *Journal of Internal Medicine*, **2019**, 286, 449-457	10.8	18
474	Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. *BMC Nephrology*, **2019**, 20, 144	2.7	15
473	Correlation of computed tomography with carotid plaque transcriptomes associates calcification with lesion-stabilization. *Atherosclerosis*, **2019**, 288, 175-185	3.1	28

472	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. *Diabetology and Metabolic Syndrome*, **2019**, 11, 32	5.6	6
471	Nutritional status of older patients on hemodialysis: Which nutritional markers can best predict clinical outcomes?. *Nutrition*, **2019**, 65, 113-119	4.8	21
470	Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. *Nutrients*, **2019**, 11,	6.7	64
469	Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape. *Journal of Nutrition*, **2019**, 149, 372-380	4.1	13
468	Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment. *Toxins*, **2019**, 11,	4.9	21
467	Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?. *Nephrology Dialysis Transplantation*, **2019**, 34, 901-907	4.3	11
466	Long-lived animals with negligible senescence: clues for ageing research. *Biochemical Society Transactions*, **2019**, 47, 1157-1164	5.1	16
465	Allostatic load and ageing: linking the microbiome and nutrition with age-related health. *Biochemical Society Transactions*, **2019**, 47, 1165-1172	5.1	23
464	Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2019**, 317, F1122-F1131	4.3	19
463	Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study. *PLoS Medicine*, **2019**, 16, e1002875	11.6	26
462	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 861-870	4.5	8
461	Obesity in Kidney Disease **2019**, 265-275		
460	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study **2019**, 11, 648		1
459	Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients. *BMC Nephrology*, **2019**, 20, 59	2.7	6
458	Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type. *Genome Biology*, **2019**, 20, 285	18.3	24
457	Inflammation in Chronic Kidney Disease **2019**, 208-223.e9		
456	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. *Cardiovascular Research*, **2019**, 115, 1557-1566	9.9	24
455	MicroRNAs in AKI and Kidney Transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 454-468	6.9	32

454	Mitochondrial dysfunction and gut microbiota imbalance: An intriguing relationship in chronic kidney disease. *Mitochondrion*, **2019**, 47, 206-209	4.9	10
453	Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients. *Calcified Tissue International*, **2019**, 104, 214-223	3.9	7
452	Effects of acute fructose loading on levels of serum uric acid-a pilot study. *European Journal of Clinical Investigation*, **2019**, 49, e13040	4.6	4
451	Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. *Journal of Nephrology*, **2019**, 32, 111-119	4.8	24
450	Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study. *Clinical Nutrition*, **2019**, 38, 429-437	5.9	13
449	Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. *Nephrology Dialysis Transplantation*, **2019**, 34, 442-448	4.3	16
448	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study. *Probiotics and Antimicrobial Proteins*, **2019**, 11, 648-654	5.5	41
447	Prevalence and Risk of Protein-Energy Wasting Assessed by Subjective Global Assessment in Older Adults With Advanced Chronic Kidney Disease: Results From the EQUAL Study. *Journal of Renal Nutrition*, **2018**, 28, 165-174	3	25
446	The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages. *Aids*, **2018**, 32, 1589-1598	3.5	19
445	Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. *Kidney and Blood Pressure Research*, **2018**, 43, 522-535	3.1	12
444	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2018**, 93, 1281-1292	9.9	41
443	Could Low-Protein Diet Modulate Nrf2 Pathway in Chronic Kidney Disease?. *Journal of Renal Nutrition*, **2018**, 28, 229-234	3	7
442	Curcumin - A promising nutritional strategy for chronic kidney disease patients. *Journal of Functional Foods*, **2018**, 40, 715-721	5.1	33
441	Novel treatment strategies for chronic kidney disease: insights from the animal kingdom. *Nature Reviews Nephrology*, **2018**, 14, 265-284	14.9	57
440	The Association of Mediterranean and DASH Diets with Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 1741-1751	12.7	15
439	Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?. *Nephrology*, **2018**, 23, 31-36	2.2	1
438	Red meat intake in chronic kidney disease patients: Two sides of the coin. *Nutrition*, **2018**, 46, 26-32	4.8	30
437	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. *BMC Pharmacology & Toxicology*, **2018**, 19, 33	2.6	11

436	Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease. *PLoS ONE*, **2018**, 13, e0195585	3.7	11
435	Bioactive food and exercise in chronic kidney disease: Targeting the mitochondria. *European Journal of Clinical Investigation*, **2018**, 48, e13020	4.6	15
434	Pregnancy-associated plasma protein A and mortality in haemodialysis. *European Journal of Clinical Investigation*, **2018**, 48, e12959	4.6	
433	The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. *PLoS ONE*, **2018**, 13, e0190410	3.7	54
432	The value of the Brazilian aï fruit as a therapeutic nutritional strategy for chronic kidney disease patients. *International Urology and Nephrology*, **2018**, 50, 2207-2220	2.3	9
431	High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. *European Journal of Clinical Investigation*, **2018**, 48, e12866	4.6	11
430	Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism. *Journal of Renal Nutrition*, **2018**, 28, 4-12	3	43
429	Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation. *Nephrology Dialysis Transplantation*, **2018**, 33, 971-977	4.3	3
428	FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. *Nephrology Dialysis Transplantation*, **2018**, 33, i257-i257	4.3	
427	SP298HIGHER MEAN CORPUSCULAR VOLUME ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i444-i444	4.3	
426	FP336HIGHER NEUTROPHIL TO LYMPHOCYTE RATIO ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i144-i145	4.3	
425	SaO066THE VARIATION IN HOSPITALISATION AND MORTALITY FOLLOWING NON-ATTENDANCE FOR HAEMODIALYSIS ACCORDING TO DIALYSIS DAY OF THE WEEK IN A EUROPEAN COHORT: FURTHER EVIDENCE OF HARM FROM THE TWO-DAY BREAK IN THREE TIMES A WEEK HAEMODIALYSIS. *Nephrology Dialysis Transplantation*, **2018**, 33, i344-i344	4.3	1
424	SaO027CHANGES IN BONE-MINERAL PARAMETERS PREDICT SUBSEQUENT MORTALITY IN HEMODIALYSIS PATIENTS - INSIGHTS FROM THE EUROPEAN ARO-COHORT. *Nephrology Dialysis Transplantation*, **2018**, 33, i326-i326	4.3	
423	Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study. *Nephron*, **2018**, 140, 249-256	3.3	6
422	FP630ASSOCIATION OF FRUIT AND VEGETABLE INTAKE WITH ALL-CAUSE MORTALITY IN HEMODIALYSIS PATIENTS (DIET-HD): A PROSPECTIVE COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i255-i25‘6	4.3	1
421	Chronic inflammation in end-stage renal disease and dialysis. *Nephrology Dialysis Transplantation*, **2018**, 33, iii35-iii40	4.3	113
420	SP323HIGH FIBRINOGEN LEVELS ARE INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). *Nephrology Dialysis Transplantation*, **2018**, 33, i452-i452	4.3	
419	Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial. *Journal of Functional Foods*, **2018**, 46, 378-383	5.1	15

418	FP662THE ASSOCIATION OF MEDITERRANEAN AND DASH DIETS WITH MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i268-i268	4.3	
417	Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. *Journal of Nephrology*, **2017**, 30, 255-262	4.8	19
416	Circulating markers of ageing and allostatic load: A slow train coming. *Practical Laboratory Medicine* , **2017**, 7, 49-54	1.7	31
415	Sclerostin-A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. *Kidney International Reports*, **2017**, 2, 481-485	4.1	5
414	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet, The*, **2017**, 390, 1888-1917	40	419
413	Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. *Nature Reviews Nephrology*, **2017**, 13, 429-442	14.9	130
412	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 909-912	4.3	7
411	The role of epigenetics in renal ageing. *Nature Reviews Nephrology*, **2017**, 13, 471-482	14.9	62
410	Nonpharmacologic Strategies to Modulate Nuclear Factor Erythroid 2-related Factor 2 Pathway in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2017**, 27, 282-291	3	13
409	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. *Journal of Bone and Mineral Metabolism*, **2017**, 35, 536-543	2.9	7
408	Does statins promote vascular calcification in chronic kidney disease?. *European Journal of Clinical Investigation*, **2017**, 47, 137-148	4.6	48
407	Genetic and environmental risk factors for chronic kidney disease. *Kidney International Supplements* , **2017**, 7, 88-106	6.3	28
406	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. *Kidney International Supplements*, **2017**, 7, 107-113	6.3	17
405	Inflammation and premature aging in advanced chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2017**, 313, F938-F950	4.3	121
404	Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time. *Kidney and Blood Pressure Research*, **2017**, 42, 877-885	3.1	8
403	Renal volumetry with magnetic resonance imaging. *Acta Radiologica Open*, **2017**, 6, 2058460117731120	1.2	4
402	Current epigenetic aspects the clinical kidney researcher should embrace. *Clinical Science*, **2017**, 131, 1649-1667	6.5	9
401	Rare progerin-expressing preadipocytes and adipocytes contribute to tissue depletion over time. *Scientific Reports*, **2017**, 7, 4405	4.9	17

400	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 1263	4.3	3
399	Inflammation and Protein-Energy Wasting in the Uremic Milieu. *Contributions To Nephrology*, **2017**, 191, 58-71	1.6	47
398	Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients. *PLoS ONE*, **2017**, 12, e0186659	3.7	35
397	expression is associated with vascular progeria in chronic kidney disease. *Aging*, **2017**, 9, 494-507	5.6	40
396	Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease. *Current Protein and Peptide Science*, **2017**, 18, 1232-1243	2.8	4
395	Therapeutics targeting persistent inflammation in chronic kidney disease. *Translational Research*, **2016**, 167, 204-13	11	70
394	Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. *Nephrology Dialysis Transplantation*, **2016**, 31, 1070-7	4.3	94
393	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. *Clinical Science*, **2016**, 130, 1147-63	6.5	112
392	Increased Telomere Attrition After Renal Transplantation-Impact of Antimetabolite Therapy. *Transplantation Direct*, **2016**, 2, e116	2.3	12
391	Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1163-72	6.9	91
390	Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2247-56	12.7	42
389	A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2016**, 9, 148-52	4.5	10
388	Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. *Journal of Internal Medicine*, **2016**, 279, 173-9	10.8	18
387	Telomere Attrition and Elongation after Chronic Dialysis Initiation in Patients with End-Stage Renal Disease. *Blood Purification*, **2016**, 41, 25-33	3.1	8
386	Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1479-86	12.7	70
385	Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0141738	3.7	185
384	Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0163826	3.7	22
383	Accelerated ageing and renal dysfunction links lower socioeconomic status and dietary phosphate intake. *Aging*, **2016**, 8, 1135-49	5.6	42

382	SP242GLOMERULAR FILTRATION RATE ESTIMATION USING BETA TRACE PROTEIN: EXTERNAL VALIDATION OF THREE EQUATIONS. *Nephrology Dialysis Transplantation*, **2016**, 31, i167-i167	4.3	
381	SP286PLASMA BETA TRACE PROTEIN PREDICTS MORTALITY IN CKD: RELATION WITH ENDOTHELIAL DYSFUNCTION. *Nephrology Dialysis Transplantation*, **2016**, 31, i183-i184	4.3	
380	MP528SKIN AUTOFLUORESCENCE (SAF), A MARKER OF TISSUE ADVANCED GLYCATED END-PRODUCTS (AGE), AND ARTERIAL STIFFNESS IN PERITONEAL DIALYSIS PATIENTS. *Nephrology Dialysis Transplantation*, **2016**, 31, i516-i516	4.3	
379	Nutrients and ageing: what can we learn about ageing interactions from animal biology?. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2016**, 19, 19-25	3.8	13
378	Dialysis modality and nutritional status are associated with variability of inflammatory markers. *Nephrology Dialysis Transplantation*, **2016**, 31, 1320-7	4.3	30
377	Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2016**, 31, 2033-2040	4.3	8
376	Climate Change and the Emergent Epidemic of CKD from Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1472-83	6.9	185
375	Development and validation of cardiovascular risk scores for haemodialysis patients. *International Journal of Cardiology*, **2016**, 216, 68-77	3.2	30
374	Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2016**, 36, 269-76	2.8	7
373	Screening for muscle wasting and dysfunction in patients with chronic kidney disease. *Kidney International*, **2016**, 90, 53-66	9.9	141
372	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. *Bone*, **2016**, 92, 50-57	4.7	27
371	Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4-Clinical Experience of a "First in Human" Study. *Kidney International Reports*, **2016**, 1, 105-113	4.1	8
370	Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. *Peritoneal Dialysis International*, **2015**, 35, 206-15	2.8	29
369	Regional variations in the relationship between arterial stiffness and adipocyte volume or number in obese subjects. *International Journal of Obesity*, **2015**, 39, 222-7	5.5	25
368	Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. *Nephrology Dialysis Transplantation*, **2015**, 30, 274-82	4.3	9
367	High levels of soluble tumor necrosis factor receptors 1 and 2 and their association with mortality in patients undergoing hemodialysis. *CardioRenal Medicine*, **2015**, 5, 89-95	2.8	12
366	Vascular Effects of Inflammation and Oxidative Stress in CKD **2015**, 51-59		
365	Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. *Kidney International*, **2015**, 88, 1356-1364	9.9	83

364	Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2015**, 35, 460-70	2.8	14
363	High cardiovascular event rates occur within the first weeks of starting hemodialysis. *Kidney International*, **2015**, 88, 1117-25	9.9	74
362	Obesity--a disease with many aetiologies disguised in the same oversized phenotype: has the overeating theory failed?. *Nephrology Dialysis Transplantation*, **2015**, 30, 1656-64	4.3	17
361	Premature aging in chronic kidney disease and chronic obstructive pulmonary disease: similarities and differences. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2015**, 18, 528-34	3.8	7
360	Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel. *PLoS ONE*, **2015**, 10, e0123509	3.7	30
359	Endostatin, Cathepsin S, and Cathepsin L, and Their Association with Inflammatory Markers and Mortality in Patients Undergoing Hemodialysis. *Blood Purification*, **2015**, 39, 259-65	3.1	11
358	Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients. *Journal of Nephrology*, **2015**, 28, 503-10	4.8	33
357	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. *Nephrology Dialysis Transplantation*, **2015**, 30, 84-91	4.3	44
356	Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease. *Journal of Internal Medicine*, **2015**, 278, 77-87	10.8	26
355	Associations between Thyroid Hormones, Calcification Inhibitor Levels and Vascular Calcification in End-Stage Renal Disease. *PLoS ONE*, **2015**, 10, e0132353	3.7	23
354	Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease. *Journal of Internal Medicine*, **2014**, 275, 71-83	10.8	29
353	Chronic kidney disease and premature ageing. *Nature Reviews Nephrology*, **2014**, 10, 732-42	14.9	215
352	Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Angiology*, **2014**, 65, 443-9	2.1	13
351	Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 690-7	6.9	37
350	Serum testosterone levels and clinical outcomes in male hemodialysis patients. *American Journal of Kidney Diseases*, **2014**, 63, 268-75	7.4	38
349	Selection of genetic and phenotypic features associated with inflammatory status of patients on dialysis using relaxed linear separability method. *PLoS ONE*, **2014**, 9, e86630	3.7	4
348	Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. *Nephrology Dialysis Transplantation*, **2014**, 29, 1633-8	4.3	54
347	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. *Nephrology Dialysis Transplantation*, **2014**, 29, 972-80	4.3	12

346	The relationship between IL-10 levels and cardiovascular events in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1207-16	6.9	36
345	IGF-1 and survival in ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 120-7	6.9	25
344	Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. *Kidney International*, **2014**, 86, 383-91	9.9	30
343	Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype. *Nephrology Dialysis Transplantation*, **2014**, 29, 964-71	4.3	9
342	Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. *Obesity*, **2014**, 22, 1373-9	8	35
341	Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 275-81	4.5	4
340	Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. *Blood Purification*, **2014**, 37, 138-45	3.1	7
339	Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. *JAMA - Journal of the American Medical Association*, **2014**, 311, 919-28	27.4	104
338	Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1720-8	6.9	259
337	Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 373-9	4.5	4
336	Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis. *Clinical and Experimental Nephrology*, **2014**, 18, 499-506	2.5	10
335	Why cachexia kills: examining the causality of poor outcomes in wasting conditions. *Journal of Cachexia, Sarcopenia and Muscle*, **2013**, 4, 89-94	10.3	94
334	Nonthyroidal illness and the cardiorenal syndrome. *Nature Reviews Nephrology*, **2013**, 9, 599-609	14.9	30
333	Kidney biomimicry--a rediscovered scientific field that could provide hope to patients with kidney disease. *Archives of Medical Research*, **2013**, 44, 584-90	6.6	8
332	Obesity and nephrology: results of a knowledge and practice pattern survey. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv99-104	4.3	26
331	Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). *Journal of Renal Nutrition*, **2013**, 23, 77-90	3	407
330	Hibernating bears (Ursidae): metabolic magicians of definite interest for the nephrologist. *Kidney International*, **2013**, 83, 207-12	9.9	39
329	Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients. *Journal of Internal Medicine*, **2013**, 273, 263-72	10.8	9

328	Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, 106-13	3	16
327	Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, e89-95	3	42
326	Can treating persistent inflammation limit protein energy wasting?. *Seminars in Dialysis*, **2013**, 26, 16-9	2.5	17
325	Uremic Toxicity **2013**, 49-77		5
324	Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. *Biochimie*, **2013**, 95, 1525-33	4.6	124
323	Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. *Obesity*, **2013**, 21, 659-64	8	43
322	Chronic kidney disease: a clinical model of premature aging. *American Journal of Kidney Diseases*, **2013**, 62, 339-51	7.4	184
321	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. *Kidney International*, **2013**, 84, 1096-107	9.9	348
320	Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. *American Journal of Nephrology*, **2013**, 37, 462-71	4.6	9
319	Subclinical versus overt obesity in dialysis patients: more than meets the eye. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv175-81	4.3	20
318	Inflammation in Chronic Kidney Disease **2013**, 79-91		
317	Anorexia and Appetite Stimulants in Chronic Kidney Disease **2013**, 645-657		2
316	Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. *Journal of Diabetes Research*, **2013**, 2013, 298019	3.9	13
315	Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 154-60	2	7
314	Obesity in CKD--what should nephrologists know?. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1727-36	12.7	134
313	Effects of hemodiafiltration on uremic inflammation. *Blood Purification*, **2013**, 35 Suppl 1, 11-7	3.1	14
312	Research update for articles published in EJCI in 2011. *European Journal of Clinical Investigation*, **2013**, 43, 1097-1110	4.6	2
311	Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. *Journal of Internal Medicine*, **2013**, 274, 584-93	10.8	27

310	Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality. *Clinical and Experimental Immunology*, **2013**, 174, 441-8	6.2	4
309	Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2013**, 28, 2356-63	4.3	34
308	Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *Journal of Nephrology*, **2013**, 26, 960-74	4.8	27
307	Effects of dopamine on leptin release and leptin gene (OB) expression in adipocytes from obese and hypertensive patients. *International Journal of Nephrology and Renovascular Disease*, **2013**, 6, 259-68	2.5	4
306	Metabolic changes in summer active and anuric hibernating free-ranging brown bears (Ursus arctos). *PLoS ONE*, **2013**, 8, e72934	3.7	36
305	Resveratrol: why is it a promising therapy for chronic kidney disease patients?. *Oxidative Medicine and Cellular Longevity*, **2013**, 2013, 963217	6.7	45
304	Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. *PLoS ONE*, **2013**, 8, e63493	3.7	35
303	Determinants and survival implications of low bone mineral density in end-stage renal disease patients. *Journal of Nephrology*, **2013**, 26, 485-94	4.8	19
302	Cardiovascular biomarkers in chronic kidney disease. *Journal of Renal Nutrition*, **2012**, 22, 120-7	3	21
301	Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. *Journal of Renal Nutrition*, **2012**, 22, 277-283	3	22
300	The complex role of adiponectin in chronic kidney disease. *Biochimie*, **2012**, 94, 2150-6	4.6	38
299	Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. *Nephrology Dialysis Transplantation*, **2012**, 27, 3615-20	4.3	38
298	Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. *European Journal of Clinical Pharmacology*, **2012**, 68, 571-7	2.8	18
297	Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents?. *Contributions To Nephrology*, **2012**, 178, 35-39	1.6	4
296	The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. *Nephrology Dialysis Transplantation*, **2012**, 27, 4030-41	4.3	60
295	Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 207-15	6.9	67
294	Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 709-15	4.3	59
293	Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 131-8	6.9	40

292	Serum albumin as predictor of nutritional status in patients with ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1446-53	6.9	109
291	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 70-5	4.3	80
290	DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. *Nephron Extra*, **2012**, 2, 159-68		15
289	Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. *PLoS ONE*, **2012**, 7, e36056	3.7	30
288	Genetic studies in chronic kidney disease: basic concepts. *Journal of Nephrology*, **2012**, 25, 141-9	4.8	3
287	Genetic studies in chronic kidney disease: interpretation and clinical applicability. *Journal of Nephrology*, **2012**, 25, 851-64	4.8	6
286	Activity-related energy expenditure of patients undergoing hemodialysis. *Journal of Renal Nutrition* , **2011**, 21, 226-34	3	22
285	Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. *Journal of Renal Nutrition*, **2011**, 21, 82-6	3	37
284	Influence of erythropoiesis-stimulating agents on glycated hemoglobin in nondiabetic kidney diseases at the start of dialysis. *American Journal of Nephrology*, **2011**, 33, 17-24	4.6	5
283	TNF-levels are not increased in inflamed patients carrying the CCR5 deletion 32. *Cytokine*, **2011**, 53, 16-8	4	7
282	Inflammation as a risk factor and target for therapy in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 662-8	3.5	80
281	Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. *European Journal of Clinical Investigation*, **2011**, 41, 498-506	4.6	12
280	Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. *Journal of Internal Medicine*, **2011**, 269, 410-9	10.8	37
279	Wasting in chronic kidney disease. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 9-25	10.3	160
278	Predialysis chronic kidney disease in 2010: Novel targets for slowing CKD progression. *Nature Reviews Nephrology*, **2011**, 7, 65-6	14.9	5
277	Diets and enteral supplements for improving outcomes in chronic kidney disease. *Nature Reviews Nephrology*, **2011**, 7, 369-84	14.9	119
276	Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. *Nephrology Dialysis Transplantation*, **2011**, 26, 239-45	4.3	22
275	Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-are similarly associated with survival in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2011**, 26, 1313-8	4.3	60

274	Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrology Dialysis Transplantation*, **2011**, 26, 3537-43	4.3	87
273	Monitoring of inflammation in patients on dialysis: forewarned is forearmed. *Nature Reviews Nephrology*, **2011**, 7, 166-76	14.9	84
272	Systemic consequences of poor oral health in chronic kidney disease patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 218-26	6.9	91
271	Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1001-8	6.9	24
270	Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 184-90	4.3	109
269	An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study. *Nephron Clinical Practice*, **2011**, 118, c143-54		18
268	Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2785-91	6.9	39
267	Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 2231-7	4.3	14
266	Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin. *Nephrology Dialysis Transplantation*, **2011**, 26, 2485-91	4.3	18
265	Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?. *Nephrology Dialysis Transplantation*, **2011**, 26, 3325-31	4.3	24
264	Like total ghrelin, acylated ghrelin is also lower in HD patients with cardiovascular disease. *Kidney International*, **2011**, 80, 783-784	9.9	
263	Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. *Kidney International*, **2011**, 79, 749-56	9.9	49
262	Association with Helicobacter pylori infection and ghrelin level in hemodialysis patients. *Kidney International*, **2011**, 80, 894	9.9	
261	Recent insights in inflammation-associated wasting in patients with chronic kidney disease. *Contributions To Nephrology*, **2011**, 171, 120-126	1.6	29
260	Impaired resistance artery function in patients with end-stage renal disease. *Clinical Science*, **2011**, 120, 525-36	6.5	30
259	Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1617-25	6.9	83
258	Dialysis in 2011: Can cardiovascular risk in dialysis patients be decreased?. *Nature Reviews Nephrology*, **2011**, 8, 72-4	14.9	6
257	Endocrine Aspects of Chronic Kidney Disease **2011**, 2122-2137		1

256	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. *Journal of Internal Medicine*, **2010**, 268, 456-67	10.8	229
255	Research update for articles published in EJCI in 2008. *European Journal of Clinical Investigation*, **2010**, 40, 770-789	4.6	0
254	Simple advice on lifestyle habits and long-term changes in biomarkers of inflammation and vascular adhesion in healthy middle-aged men. *European Journal of Clinical Nutrition*, **2010**, 64, 1450-6	5.2	13
253	Genetic loci influencing kidney function and chronic kidney disease. *Nature Genetics*, **2010**, 42, 373-5	36.3	205
252	Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2010**, 25, 562-8	4.3	94
251	Hemoglobin variability does not predict mortality in European hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1765-75	12.7	262
250	Cardiovascular Disease in Chronic Kidney Disease **2010**, 935-950		4
249	Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2213-9	6.9	66
248	Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. *Nephrology Dialysis Transplantation*, **2010**, 25, 901-6	4.3	44
247	Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. *Nephrology Dialysis Transplantation*, **2010**, 25, 3033-8	4.3	61
246	Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. *Nephrology Dialysis Transplantation*, **2010**, 25, 3717-23	4.3	15
245	Clinical importance of an elevated circulating chemerin level in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 4017-23	4.3	35
244	Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. *Clinica Chimica Acta*, **2010**, 411, 2079-82	6.2	27
243	The emerging pleiotrophic role of adipokines in the uremic phenotype. *Current Opinion in Nephrology and Hypertension*, **2010**, 19, 37-42	3.5	42
242	Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *European Journal of Clinical Pharmacology*, **2010**, 66, 269-73	2.8	9
241	Inflammation in end-stage renal disease--what have we learned in 10 years?. *Seminars in Dialysis*, **2010**, 23, 498-509	2.5	213
240	Inflammation as a target for improving health in chronic kidney disease. *F1000 Medicine Reports*, **2010**, 2, 88		3
239	Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Traditional, Nontraditional, and Uremia-related Threats **2010**, 91-104		3

238	Low serum testosterone increases mortality risk among male dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 613-20	12.7	138
237	Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4 Suppl 1, S49-55	6.9	137
236	Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness **2009**, 2, i18-i26		54
235	Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 110-8	6.9	93
234	Low serum uric acid level is a risk factor for death in incident hemodialysis patients. *American Journal of Nephrology*, **2009**, 29, 79-85	4.6	72
233	Systemic and local inflammation in peritoneal dialysis: mechanisms, biomarkers and effects on outcome. *Contributions To Nephrology*, **2009**, 163, 132-139	1.6	9
232	Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. *American Journal of Nephrology*, **2009**, 29, 447-53	4.6	17
231	N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. *American Journal of Nephrology*, **2009**, 29, 516-23	4.6	16
230	Adiponectin in chronic kidney disease: Dr Jekyll and Mr Hyde. *Kidney International*, **2009**, 75, 120-1; author reply 121	9.9	1
229	Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2009**, 24, 3454-60	4.3	24
228	Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 3468-73	4.3	21
227	CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1641-9	12.7	59
226	Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 535-41	6.9	54
225	Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. *American Journal of Kidney Diseases*, **2009**, 53, 1024-33	7.4	94
224	Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. *Journal of Internal Medicine*, **2009**, 265, 708-16	10.8	17
223	Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?. *Clinical Transplantation*, **2009**, 23, 241-8	3.8	40
222	The role of EUTox in uremic toxin research. *Seminars in Dialysis*, **2009**, 22, 323-8	2.5	25
221	Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. *Seminars in Dialysis*, **2009**, 22, 351-6	2.5	33

220	Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. *Seminars in Dialysis*, **2009**, 22, 381-6	2.5	62
219	Leptin and uremic protein-energy wasting--the axis of eating. *Seminars in Dialysis*, **2009**, 22, 387-90	2.5	8
218	The role of oxidative stress in chronic kidney disease. *Seminars in Dialysis*, **2009**, 22, 405-8	2.5	96
217	Genetics/Genomics in chronic kidney disease--towards personalized medicine?. *Seminars in Dialysis*, **2009**, 22, 417-22	2.5	20
216	Conservative treatment of the uremic syndrome. *Seminars in Dialysis*, **2009**, 22, 449-53	2.5	1
215	Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. *American Journal of Kidney Diseases*, **2009**, 54, 1072-80	7.4	64
214	Does the uremic milieu affect the epigenotype?. *Journal of Renal Nutrition*, **2009**, 19, 82-5	3	10
213	Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. *Current Opinion in Lipidology*, **2009**, 20, 3-9	4.4	22
212	Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. *Molecular Medicine*, **2009**, 15, 70-5	6.2	43
211	Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. *Clinical Nephrology*, **2009**, 72, 87-96	2.1	30
210	Cardiovascular Disease and Inflammation **2009**, 679-695		
209	Protein-Energy Malnutrition/Wasting During Peritoneal Dialysis **2009**, 611-647		2
208	Vascular Calcification in Chronic Kidney Disease **2009**, 697-711		2
207	Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. *Journal of Nephrology*, **2009**, 22, 774-82	4.8	23
206	Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. *European Journal of Clinical Investigation*, **2008**, 38, 804-11	4.6	43
205	Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. *Journal of Internal Medicine*, **2008**, 263, 302-12	10.8	137
204	Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. *Clinical Nutrition*, **2008**, 27, 557-64	5.9	185
203	Telomere biology alterations as a mortality risk factor in CKD. *American Journal of Kidney Diseases*, **2008**, 51, 1076-7	7.4	1

202	Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. *Clinica Chimica Acta*, **2008**, 393, 114-8	6.2	44
201	Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. *Clinica Chimica Acta*, **2008**, 395, 106-10	6.2	49
200	Appetite disorders in uremia. *Journal of Renal Nutrition*, **2008**, 18, 107-13	3	75
199	Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. *Advances in Clinical Chemistry*, **2008**, 46, 217-62	5.8	26
198	Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 976-85	6.9	92
197	Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 61-8	6.9	96
196	Is UCP2 gene polymorphism associated with decreased resting energy expenditure in nondialyzed chronic kidney disease patients?. *Journal of Renal Nutrition*, **2008**, 18, 489-94	3	7
195	Aspects of immune dysfunction in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 1526-33	6.9	580
194	ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 388-95	12.7	70
193	Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. *Nephron Clinical Practice*, **2008**, 108, c233-40		36
192	The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. *Nephron Experimental Nephrology*, **2008**, 109, e71-8		38
191	Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality. *Blood Purification*, **2008**, 26, 284-90	3.1	17
190	Lipoprotein lipase 1595 c/g and hepatic lipase -480 c/t polymorphisms--impact on lipid profile in incident dialysis patients. *Blood Purification*, **2008**, 26, 555-60	3.1	2
189	Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?. *American Journal of Nephrology*, **2008**, 28, 669-76	4.6	24
188	Epigenetics and the uremic phenotype: a matter of balance. *Contributions To Nephrology*, **2008**, 161, 55-62	1.6	11
187	Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. *Nephrology Dialysis Transplantation*, **2008**, 23, 1621-7	4.3	81
186	Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. *Blood Purification*, **2008**, 26, 204-10	3.1	30
185	Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 505-21	6.9	380

184	Cytokine dysregulation in chronic kidney disease: how can we treat it?. *Blood Purification*, **2008**, 26, 291-9	3.1	76
183	The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. *QJM - Monthly Journal of the Association of Physicians*, **2008**, 101, 397-405	2.7	52
182	Role of fat mass and adipokines in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2008**, 17, 25-31	3.5	43
181	Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. *American Journal of Clinical Nutrition*, **2008**, 87, 1860-6	7	180
180	High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). *Molecular Medicine*, **2008**, 14, 109-15	6.2	76
179	TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease. *Applied Surface Science*, **2008**, 255, 1177-1180	6.7	25
178	Understanding the role of genetic polymorphisms in chronic kidney disease. *Pediatric Nephrology*, **2008**, 23, 1941-9	3.2	10
177	Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2008**, 23, 959-65	4.3	87
176	Resolved: being fat is good for dialysis patients: the Godzilla effect: con. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1062-4	12.7	19
175	Statins to Treat Chronic Inflammation in Dialysis Patients Is this Feasible?. *Peritoneal Dialysis International*, **2007**, 27, 254-257	2.8	6
174	Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism. *Current Nutrition and Food Science*, **2007**, 3, 37-46	0.7	1
173	Identifying and Managing Malnutrition Stemming from Different Causes. *Peritoneal Dialysis International*, **2007**, 27, 239-244	2.8	7
172	Reply to A Molfino et al. *American Journal of Clinical Nutrition*, **2007**, 86, 1551-1553	7	6
171	Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. *Journal of Internal Medicine*, **2007**, 261, 488-99	10.8	304
170	Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. *Journal of Internal Medicine*, **2007**, 262, 215-23	10.8	38
169	Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *Journal of Internal Medicine*, **2007**, 262, 690-701	10.8	102
168	Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. *Seminars in Dialysis*, **2007**, 20, 523-9	2.5	13
167	Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. *American Journal of Kidney Diseases*, **2007**, 49, 237-44	7.4	92

166	Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. *Nephrology Dialysis Transplantation*, **2007**, 22, 196-202	4.3	28
165	The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrology Dialysis Transplantation*, **2007**, 22, 209-17	4.3	50
164	Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 889-97	6.9	124
163	Association between oestrogen receptor alpha gene polymorphism and mortality in female end-stage renal disease patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 2571-7	4.3	4
162	Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 3586-92	4.3	12
161	Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney International*, **2007**, 72, 549-56	9.9	69
160	Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. *Blood Purification*, **2007**, 25, 210-8	3.1	15
159	Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. *American Journal of Clinical Nutrition*, **2007**, 85, 695-701	7	182
158	Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. *American Journal of Clinical Nutrition*, **2007**, 86, 633-8	7	204
157	OPTAIInfluence of inflammation/infection on anaemia therapy in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, iii7-iii12	4.3	4
156	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. *Clinica Chimica Acta*, **2007**, 379, 87-94	6.2	43
155	Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. *Journal of Renal Nutrition*, **2007**, 17, 132-7	3	12
154	Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *Journal of Renal Nutrition*, **2007**, 17, 17-22	3	6
153	Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis. *Peritoneal Dialysis International*, **2007**, 27, 205-209	2.8	36
152	Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. *Clinical Nephrology*, **2007**, 68, 1-9	2.1	35
151	Oral health and pro-inflammatory status in end-stage renal disease patients. *Oral Health & Preventive Dentistry*, **2007**, 5, 235-44	1.9	14
150	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *American Journal of Kidney Diseases*, **2006**, 47, 139-48	7.4	371
149	J-shaped mortality relationship for uric acid in CKD. *American Journal of Kidney Diseases*, **2006**, 48, 761-71	7.4	172

148	Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. *American Journal of Kidney Diseases*, **2006**, 48, 916-25	7.4	51
147	Adipose tissue and inflammation in chronic kidney disease. *Contributions To Nephrology*, **2006**, 151, 165-174	1.6	33
146	Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. *Blood Purification*, **2006**, 24, 575-82	3.1	9
145	Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. *Blood Purification*, **2006**, 24, 196-202	3.1	33
144	Being an inflamed peritoneal dialysis patient - a Dante's journey. *Contributions To Nephrology*, **2006**, 150, 144-151	1.6	16
143	Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. *Nephrology Dialysis Transplantation*, **2006**, 21, 1603-10	4.3	54
142	C-reactive protein--does it promote vascular disease?. *Nephrology Dialysis Transplantation*, **2006**, 21, 2718-20	4.3	10
141	Adipokine signaling in the peritoneal dialysis patient. *Contributions To Nephrology*, **2006**, 150, 166-173	1.6	13
140	Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 281-7	6.9	33
139	Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?. *Antioxidants and Redox Signaling*, **2006**, 8, 2169-73	8.4	26
138	New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. *Nephrologie Et Therapeutique*, **2006**, 2, 111-9	0.6	45
137	Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. *Journal of Renal Nutrition*, **2006**, 16, 119-24	3	19
136	Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Seminars in Nephrology*, **2006**, 26, 14-9	4.8	5
135	Systemic and Intraperitoneal Interleukin-6 System during the First Year of Peritoneal Dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	88
134	Inflammation in end-stage renal disease: the hidden enemy. *Nephrology*, **2006**, 11, 36-41	2.2	140
133	Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. *European Journal of Clinical Nutrition*, **2006**, 60, 718-26	5.2	37
132	Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney International*, **2006**, 69, 596-604	9.9	168
131	Response to Resistin letters. *Kidney International*, **2006**, 70, 1372	9.9	

130	Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney International*, **2006**, S138-45	9.9	9
129	Inflammation and wasting in chronic kidney disease: Partners in crime. *Kidney International*, **2006**, 70, S8-S13	9.9	54
128	Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	36
127	Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. *Blood Purification*, **2005**, 23, 384-93	3.1	21
126	Inflammation in end-stage renal disease--a fire that burns within. *Contributions To Nephrology*, **2005** , 149, 185-199	1.6	65
125	Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. *Blood Purification*, **2005**, 23, 275-81	3.1	8
124	Homocysteine in uraemia--a puzzling and conflicting story. *Nephrology Dialysis Transplantation*, **2005**, 20, 16-21	4.3	116
123	Serum albumin: a late-reacting negative acute-phase protein in clinically evident inflammation in dialysis patients. *Nephrology Dialysis Transplantation*, **2005**, 20, 658-9; author reply 659-60	4.3	15
122	Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. *Atherosclerosis*, **2005**, 180, 333-40	3.1	59
121	Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. *Atherosclerosis*, **2005**, 182, 105-11	3.1	28
120	Why do dialysis patients develop a heart of stone and bone of china?. *Blood Purification*, **2005**, 23, 203-10	3.1	19
119	Adipose tissue and its relation to inflammation: the role of adipokines. *Journal of Renal Nutrition*, **2005**, 15, 131-6	3	91
118	Kidney insufficiency and nutrient-based modulation of inflammation. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2005**, 8, 388-96	3.8	31
117	Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. *Seminars in Dialysis*, **2005**, 18, 322-30	2.5	20
116	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. *Kidney International*, **2005**, 67, 1216-33	9.9	588
115	Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney International*, **2005**, 67, 2383-92	9.9	232
114	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. *Kidney International*, **2005**, 67, 2477-87	9.9	87
113	Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney International*, **2005**, 68, 1857-65	9.9	89

112	Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. *Kidney International*, **2005**, 68, 2368-74	9.9	123
111	End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. *Journal of Internal Medicine*, **2005**, 258, 1-12	10.8	29
110	Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *American Journal of Kidney Diseases*, **2005**, 46, 387-405	7.4	125
109	Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *American Journal of Kidney Diseases*, **2005**, 46, 628-34	7.4	62
108	Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatric Nephrology*, **2005**, 20, 714-20	3.2	37
107	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-349	7	56
106	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-9	7	46
105	Adipokines in Chronic Kidney Disease Fat Tissue Gives Nephrologists a Message. *Peritoneal Dialysis International*, **2005**, 25, 340-342	2.8	15
104	Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3110-20	12.7	81
103	C-reactive protein in end-stage renal disease: are there reasons to measure it?. *Blood Purification*, **2005**, 23, 72-8	3.1	49
102	Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients?. *Nephron Clinical Practice*, **2005**, 101, c187-9		2
101	Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Brazilian Journal of Medical and Biological Research*, **2005**, 38, 783-8	2.8	26
100	Truncal fat mass as a contributor to inflammation in end-stage renal disease. *American Journal of Clinical Nutrition*, **2004**, 80, 1222-9	7	159
99	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-339	2.8	76
98	Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2004**, 19, 1823-8	4.3	34
97	Impact of residual renal function on volume status in chronic renal failure. *Blood Purification*, **2004**, 22, 285-92	3.1	38
96	Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. *Nephrology Dialysis Transplantation*, **2004**, 19, 421-6	4.3	97
95	Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. *Nephrology Dialysis Transplantation*, **2004**, 19, 972-6	4.3	53

94	Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. *Nephrology Dialysis Transplantation*, **2004**, 19, 1497-506	4.3	48
93	The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. *Nephrology Dialysis Transplantation*, **2004**, 19, 2803-9	4.3	52
92	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 3112-6	4.3	17
91	Chronic systemic inflammation in dialysis patients: an update on causes and consequences. *ASAIO Journal*, **2004**, 50, lii-lvii	3.6	41
90	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. *Hemodialysis International*, **2004**, 8, 102-102	1.7	
89	Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. *Hemodialysis International*, **2004**, 8, 118-29	1.7	57
88	Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney International*, **2004**, 65, 274-81	9.9	125
87	Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Kidney International*, **2004**, 66, 46-50	9.9	45
86	Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Seminars in Dialysis*, **2004**, 17, 505-15	2.5	33
85	Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. *Scandinavian Journal of Urology and Nephrology*, **2004**, 38, 405-16		95
84	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. *American Journal of Kidney Diseases*, **2004**, 44, 455-465	7.4	34
83	Chronic inflammation in peritoneal dialysis: the search for the holy grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-39	2.8	29
82	Anaemia and inflammation: what are the implications for the nephrologist?. *Nephrology Dialysis Transplantation*, **2003**, 18 Suppl 8, viii17-22	4.3	27
81	The importance of diabetic nephropathy in current nephrological practice. *Nephrology Dialysis Transplantation*, **2003**, 18, 1716-25	4.3	42
80	Influence of Peritoneal Transport Rate, Inflammation, and Fluid Removal on Nutritional Status and Clinical Outcome in Prevalent Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2003**, 23, 174-183	2.8	91
79	Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. *Nephrology Dialysis Transplantation*, **2003**, 18, 590-7	4.3	95
78	Chronic inflammation in PD patients. *Contributions To Nephrology*, **2003**, 140, 104-11	1.6	7
77	Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. *American Journal of Kidney Diseases*, **2003**, 41, S89-95	7.4	38

76	Associations between circulating inflammatory markers and residual renal function in CRF patients. *American Journal of Kidney Diseases*, **2003**, 41, 1212-8	7.4	319
75	Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *Journal of Internal Medicine*, **2003**, 253, 153-60	10.8	45
74	Gene Expression Analysis in Inflamed and Non-inflamed Hemodialysis (HD) Patients Using a cDNA Microarray. *Hemodialysis International*, **2003**, 7, 73-104	1.7	
73	Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney International*, **2003**, 63, 1934-43	9.9	1067
72	Beyond the membrane--the role of new PD solutions in enhancing global biocompatibility. *Kidney International*, **2003**, S124-32	9.9	8
71	A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Kidney International*, **2003**, S172-6	9.9	93
70	Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. *Kidney International*, **2003**, S162-7	9.9	24
69	End-stage renal disease: a state of chronic inflammation and hyperleptinemia. *European Journal of Clinical Investigation*, **2003**, 33, 527-8	4.6	21
68	Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease **2003**, 13, 144-8		59
67	Inflammation and nutrition in renal insufficiency. *Advances in Chronic Kidney Disease*, **2003**, 10, 155-69		78
66	Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?. *Advances in Chronic Kidney Disease*, **2003**, 10, 332-45		31
65	Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrology Dialysis Transplantation*, **2003**, 18, 1272-80	4.3	540
64	Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. *Respiratory Medicine*, **2003**, 97, 308-16	4.6	15
63	Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1927-39	12.7	182
62	Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1614-22	12.7	117
61	Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. *Peritoneal Dialysis International*, **2003**, 23, 174-83	2.8	18
60	Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. *American Journal of Kidney Diseases*, **2002**, 39, 274-82	7.4	167
59	What are the causes of protein-energy malnutrition in chronic renal insufficiency?. *American Journal of Kidney Diseases*, **2002**, 39, 422-5	7.4	19

58	Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. *American Journal of Kidney Diseases*, **2002**, 40, 480-8	7.4	43
57	The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney International*, **2002**, 62, 1524-38	9.9	846
56	Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?. *Kidney International*, **2002**, 62, 1791-8	9.9	137
55	Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?. *Kidney International*, **2002**, 103-8	9.9	134
54	Inflammation in end-stage renal disease: sources, consequences, and therapy. *Seminars in Dialysis*, **2002**, 15, 329-37	2.5	286
53	Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. *European Journal of Clinical Investigation*, **2002**, 32, 811-7	4.6	57
52	A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. *Nephrology Dialysis Transplantation*, **2002**, 17, 1266-74	4.3	136
51	Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective. *Blood Purification*, **2002**, 20, 454-8	3.1	43
50	Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. *Nephrology Dialysis Transplantation*, **2002**, 17, 1480-6	4.3	160
49	Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. *Nephrology Dialysis Transplantation*, **2002**, 17, 1684-8	4.3	290
48	The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 11, 28-31	4.3	405
47	Inflammation in end-stage renal failure: could it be treated?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 8, 33-8; discussion 40	4.3	109
46	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 5, 32-7	4.3	67
45	Molecular genetics in renal medicine: what can we hope to achieve?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 3, 5-11	4.3	17
44	Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, **2001**, 19, 53-61	3.1	168
43	Uremic Toxicity: Present State of the Art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	209
42	Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. *Nephrology Dialysis Transplantation*, **2001**, 16, 2240-5	4.3	113
41	Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purification*, **2001**, 19, 143-51	3.1	119

40	Malnutrition, Inflammation, and Atherosclerosis in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2001**, 21, 157-162	2.8	76
39	Uremic toxicity: present state of the art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	51
38	Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. *Nephrology Dialysis Transplantation*, **2000**, 15, 1624-30	4.3	140
37	Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. *Kidney International*, **2000**, 57, 1713-9	9.9	50
36	Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney International*, **2000**, 57, 1727-35	9.9	145
35	LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *European Journal of Clinical Investigation*, **2000**, 30, 866-70	4.6	18
34	Biocompatibility of New Peritoneal Dialysis Solutions: What Can We Hope to Achieve?. *Peritoneal Dialysis International*, **2000**, 20, 57-67	2.8	30
33	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrology Dialysis Transplantation*, **2000**, 15, 953-60	4.3	599
32	Physical activity promotes health also among dialysis patients. *International Journal of Cardiology*, **2000**, 72, 299-300	3.2	5
31	Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *American Journal of Kidney Diseases*, **2000**, 36, 1213-25	7.4	203
30	Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. *Journal of the American Society of Nephrology: JASN*, **2000**, 11, 1303-1309	12.7	138
29	Leptin and its clinical implications in chronic renal failure. *Mineral and Electrolyte Metabolism*, **1999**, 25, 298-302		24
28	Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. *Journal of Internal Medicine*, **1999**, 246, 503-7	10.8	94
27	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney International*, **1999**, 55, 1899-911	9.9	1196
26	High serum hyaluronan indicates poor survival in renal replacement therapy. *American Journal of Kidney Diseases*, **1999**, 34, 1083-8	7.4	58
25	The enigma of increasing serum leptin levels during peritoneal dialysis. *American Journal of Kidney Diseases*, **1999**, 34, 947-50	7.4	5
24	Molecular studies of leptin: implications for renal disease. *Nephrology Dialysis Transplantation*, **1999** , 14, 1103-12	4.3	33
23	Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney International*, **1998**, 54, 1267-75	9.9	122

22	Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. *Kidney International*, **1998**, 53, 1336-42	9.9	56
21	Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure?. *Kidney International*, **1998**, 53, 1430-1	9.9	17
20	A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrology Dialysis Transplantation*, **1998**, 13, 2594-600	4.3	61
19	Hormonal status in critically ill patients with or without acute renal failure **1998**, 391-403		
18	A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. *Nephrology Dialysis Transplantation*, **1997**, 12, 1600-7	4.3	
17	Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. *Nephrology Dialysis Transplantation*, **1997**, 12, 141-4	4.3	19
16	Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. *Nephrology Dialysis Transplantation*, **1997**, 12, 1321-5	4.3	85
15	Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. *Acta Diabetologica*, **1997**, 34, 10-7	3.9	2
14	Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *European Journal of Clinical Investigation*, **1997**, 27, 169-77	4.6	16
13	Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. *Journal of the American Society of Nephrology: JASN*, **1997**, 8, 1423-30	12.7	154
12	Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. *Nephron*, **1996**, 72, 135-44	3.3	48
11	Lipoprotein(a) in chronic renal disease. *Mineral and Electrolyte Metabolism*, **1996**, 22, 16-21		3
10	Effect of insulin on renal sodium handling and renal haemodynamics in insulin-dependent (type 1) diabetes mellitus patients. *Acta Diabetologica*, **1995**, 32, 230-4	3.9	6
9	Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. *Journal of the American Society of Nephrology: JASN*, **1995**, 5, 1751-60	12.7	27
8	Insulin causes renal vasodilatation independently of renal prostaglandins in healthy humans. *Nephrology Dialysis Transplantation*, **1994**, 9, 1728-33	4.3	5
7	Lipoprotein(a) in nephrotic syndrome. *Kidney International*, **1993**, 44, 1116-23	9.9	47
6	Renal haemodynamics and tubular sodium handling following volume expansion with sodium chloride (NaCl) and glucose in healthy humans. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1992**, 52, 837-46	2	17
5	Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. *Diabetologia*, **1992**, 35, 1042-8	10.3	87

4	Decreased renal clearance of sodium in cystic fibrosis. *Acta Paediatrica, International Journal of Paediatrics*, **1991**, 80, 194-8	3.1	16
3	Impaired intrarenal dopamine production following intravenous sodium chloride infusion in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*, **1991**, 34, 114-8	10.3	25
2	Factors influencing progression in patients with chronic renal failure. *Journal of Internal Medicine*, **1989**, 226, 183-8	10.8	17
1	Clostridium difficile-associated diarrhoea in uremic patients. *European Journal of Clinical Microbiology and Infectious Diseases*, **1987**, 6, 352-6	5.3	29